VIDEO: T-cell-directed therapy targeting HER2 under investigation for solid tumors
Click Here to Manage Email Alerts
Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed a trial-in-progress investigating autologous T-cell antigen coupler T cells targeting HER2 in relapsed or refractory solid tumors in a video interview with Healio.
Schlechter, who presented on the trial at ASCO Gastrointestinal Cancers Symposium, said this uses “an engineered T cell where the [T-cell receptor (TCR)] synapse ... is native and the cell is modified in other ways to increase persistence and to engage HER2 as a target to tightly bind to HER2 without the uncontrolled activation of the TCR pathway.”
Schlechter said it’s important to target HER2 and find “ways to use T-cell therapies that are not [chimeric antigen receptor T-cell therapies] that can better differentiate on-target intended consequences and on-target unintended consequences, because these are potentially dangerous agents that we have to be really careful what target we hit and how we hit it.
“There’s two important innovations here: one, HER2 is common and any T-cell therapy that’s successful in HER2 I think is going to be a big deal; two, it’s a proof-of-concept that there’s technology out there that we can use broadly in solid tumors because solid tumors are just different than hematologic malignancies,” he continued.
Reference:
- Schlechter BL, et al. Abstract TPS816. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Collapse
Healio Interview
Click Here to Manage Email Alerts